---
title: "Famous fund managers' second-quarter portfolio adjustments revealed: increasing positions in military industry, with divergences in the pharmaceutical sector"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/247664983.md"
description: "The second-quarter portfolio adjustments of well-known fund managers show significant divergence in the pharmaceutical sector, with some fund managers increasing their positions in companies like Orient Biotech, while others choose to reduce their holdings in Mabwell. The market's view on pharmaceutical stocks mainly revolves around factors such as valuation, performance, research and development risks, and policy impacts. In addition, the military industry sector has received more attention, with institutions warning to be cautious of short-term volatility risks"
datetime: "2025-07-08T13:41:31.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/247664983.md)
  - [en](https://longbridge.com/en/news/247664983.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/247664983.md)
---

# Famous fund managers' second-quarter portfolio adjustments revealed: increasing positions in military industry, with divergences in the pharmaceutical sector

Recently, with some listed companies disclosing their top ten circulating shareholders, the repositioning trends of certain well-known fund managers in the first half of the year have been revealed. Journalists have found that there are still divergences among fund managers regarding pharmaceutical stocks. For example, in the second quarter, while Dongfang Biotech, which was heavily increased by Wan Minyuan, saw some fund managers choose to reduce their holdings; on the other hand, Mabwell, which Jin Xiaofei has held for a long time, was reduced by Lu Bin. Interviewees pointed out that the market's divergence on the pharmaceutical sector mainly focuses on valuation versus performance realization, risks and returns of innovative drug development, market sentiment and capital flow, policy impacts, and short-term volatility. In addition, recently, public funds have shown increased attention to the military industry sector. Some institutions have warned that the trading in the military sector is heating up, and caution is needed regarding short-term volatility risks

### Related Stocks

- [688298.CN](https://longbridge.com/en/quote/688298.CN.md)
- [688062.CN](https://longbridge.com/en/quote/688062.CN.md)

## Related News & Research

- [Mabwell Wins Wider China Indications for Denosumab Biosimilar as Global Push Accelerates](https://longbridge.com/en/news/287103520.md)
- [Aker BP insider sells shares worth NOK 1.17 million](https://longbridge.com/en/news/287249459.md)
- [Orkla (OB:ORK) Margin Improvement Challenges Cautious Earnings Narratives Heading Into Q1 2026](https://longbridge.com/en/news/287134604.md)
- [Phase 3-ready cancer biotech Parabilis Medicines files for a $100 million IPO](https://longbridge.com/en/news/286972125.md)
- [China's Bio-Thera Gets US Nod for Golimumab Biosimilar](https://longbridge.com/en/news/286880573.md)